Ignite Creation Date:
2025-12-24 @ 9:23 PM
Ignite Modification Date:
2026-01-05 @ 10:10 AM
Study NCT ID:
NCT04570332
Status:
COMPLETED
Last Update Posted:
2025-11-26
First Post:
2020-09-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
BO-112 With Pembrolizumab in Unresectable Malignant Melanoma
Sponsor:
Highlight Therapeutics
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
BOT112-03
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None
Collaborators
Collaborators
| Name | Class | View |
|---|---|---|
| None | INDUSTRY | View |